Sialorrhea Treatment Market By Treatment Type (Oral Anticholinergic Medicines, Botulinum Toxin Injections, Surgical and Interventional Procedures, Radiotherapy); By Disease Indication (Parkinson’s Disease, Cerebral Palsy, Amyotrophic Lateral Sclerosis, Stroke and Traumatic Brain Injury, Clozapine-Induced Sialorrhea, Neurodevelopmental Disorders); By Patient Group (Pediatric Patients, Adult Patients); By End User (Hospitals, Neurology Clinics, Pediatric Specialty Clinics, Rehabilitation Centers, ENT Clinics, Long-Term Care and Home-Care Settings); By Region, Segment Revenue Estimation, Forecast, 2026–2032

Sialorrhea Treatment Market Gains from Neurologic Disease Burden, Botulinum Toxin Access, and Pediatric Drooling Control

The Global Sialorrhea Treatment Market was valued at USD 734 million in 2025 and is projected to reach USD 1.08 billion by 2032, growing at a CAGR of 5.7%, according to Strategic Market Research.

 

The Sialorrhea Treatment Market serves a chronic neurologic symptom that remains undertreated despite its effect on swallowing, speech, aspiration risk, oral care, skin breakdown, medication adherence, and caregiver workload. Demand is concentrated in Parkinson’s disease, cerebral palsy, amyotrophic lateral sclerosis, stroke, traumatic brain injury, neurodevelopmental disorders, and clozapine-treated schizophrenia. Mild drooling usually stays outside formal treatment, while persistent or severe sialorrhea moves patients toward anticholinergic medicines, botulinum toxin injections, specialist procedures, and multidisciplinary care.

 

Oral anticholinergics support routine pediatric and neurologic prescribing because they are familiar, titratable, and easier to initiate than gland injections. Botulinum toxin products capture higher-value treatment cycles where systemic anticholinergic effects limit dose escalation or where patients need localized salivary control. Reimbursement for injection services, pediatric approvals, neurologic specialist access, and repeat-treatment intervals now matter as much as clinical efficacy.

 

Neurologic Patient Pools Shape Treated Demand

Parkinson’s disease provides one of the largest adult treatment pools. More than 10 million people live with Parkinson’s disease globally, and the U.S. Parkinson’s population is estimated at about 1.1 million, rising toward 1.2 million by 2030. Drooling prevalence in Parkinson’s disease ranges from 32% to 74% across studies, with a pooled estimate of 56%, although frequent drooling is reported by a smaller 22%–26% share of patients. Treatment demand therefore depends on severity, social burden, aspiration concerns, and neurologist recognition rather than the full prevalence estimate.

Cerebral palsy anchors the pediatric market. The American Academy for Cerebral Palsy and Developmental Medicine estimates sialorrhea in around 40% of children and young people with cerebral palsy, while a systematic review reported pooled drooling prevalence of 44.0%. Pediatric demand differs from adult Parkinson’s care because parents, schools, therapists, dentists, and rehabilitation teams influence treatment decisions. Products that reduce bib changes, oral irritation, aspiration events, and caregiver time have stronger practical value than therapies that only reduce measured salivary flow.

ALS creates a smaller but clinically urgent segment. An analysis across 17 studies estimated pooled sialorrhea prevalence at 30.8%, with severe sialorrhea in about 10.5% of ALS patients. Secretion management in ALS is complicated by swallowing weakness, respiratory decline, cough impairment, and palliative-care needs. Anticholinergics, botulinum toxin, suctioning, radiotherapy, and supportive care compete on tolerability and respiratory safety rather than symptom reduction alone.

Clozapine-induced sialorrhea adds a psychiatry-linked demand pool. Published estimates often place clozapine-related hypersalivation between 30% and 80%, and some observational studies report even higher rates. This segment matters because uncontrolled salivation can reduce adherence to clozapine, one of the most important medicines for treatment-resistant schizophrenia. Prescribing is usually dominated by off-label anticholinergic strategies rather than botulinum toxin, but persistent symptoms create demand for safer long-term options.

 

Oral Anticholinergics Remain the First Practical Treatment Step

Glycopyrrolate and glycopyrronium products remain widely used because they can be started without a procedure. CUVPOSA is indicated in the United States to reduce chronic severe drooling in children aged 3 to 16 years with neurologic conditions. In the pivotal placebo-controlled study, 75% of treated patients met the response criterion at eight weeks versus 11% with placebo, using a three-point or greater improvement on the modified Teacher’s Drooling Scale.

Systemic tolerability limits the expansion of oral therapy. In the CUVPOSA study, dry mouth and vomiting each occurred in 40% of treated patients compared with 11% on placebo. Constipation occurred in 35% versus 22%, flushing in 30% versus 17%, and urinary retention in 15% versus none. Dose escalation becomes difficult when caregivers are already managing feeding issues, constipation, heat intolerance, bladder symptoms, or multiple neurologic medicines.

Europe has a clear pediatric route through Sialanar. The European Medicines Agency authorizes glycopyrronium bromide for severe drooling in children and adolescents aged three years and above with neurologic conditions. EMA reported that about 74% of patients receiving glycopyrronium bromide achieved at least a three-point mTDS reduction after eight weeks, compared with 18% on placebo. Pediatric oral therapy keeps a strong position where families prefer non-invasive treatment and where injection access is limited.

Longer-duration data give oral glycopyrronium a stronger evidence base, but constipation and titration remain central to use. The 2025 SALIVA extension study in children and adolescents with neurodisabilities and severe sialorrhea reported a median 39-point Drooling Impact Scale improvement over 36 weeks among children who continued treatment. Responder rates reached 81.1%, and 70.3% met the study’s good-responder definition. Constipation remained the most frequent treatment-related adverse event, keeping monitoring and dose adjustment part of routine care.

 

Botulinum Toxin Converts Chronic Drooling into Repeat Specialist Treatment

Botulinum toxin products occupy the higher-value segment because they provide localized salivary-gland treatment and repeat dosing. XEOMIN is approved in the United States for chronic sialorrhea in patients aged two years and older. Adult dosing is 100 units injected into the parotid and submandibular glands, with retreatment no more frequently than every 16 weeks. The repeat-cycle model supports specialist clinic revenue, ultrasound-guided administration, and product-linked procedural planning.

Adult SIAXI data support XEOMIN’s position in neurologic sialorrhea. The pivotal study enrolled 184 adults with chronic sialorrhea associated with Parkinson’s disease, atypical parkinsonism, stroke, or traumatic brain injury. At week four, XEOMIN 100 units reduced unstimulated salivary flow by −0.13 g/min versus −0.04 g/min with placebo, with statistical significance at p=0.004. Global Impression of Change also favored XEOMIN, and 151 patients completed the extension period lasting up to 64 weeks.

Pediatric labeling gives XEOMIN a broader age-based position than most drooling therapies. The pediatric program included 216 patients aged 6–17 years and 35 patients aged 2–5 years, with subsequent extension data across repeat cycles. A product that spans children, adolescents, and adults can fit neurology, rehabilitation, and ENT pathways across long-term neurologic disability rather than only one age segment.

MYOBLOC remains the main botulinum toxin B option for adult chronic sialorrhea. The U.S. label recommends 1,500 to 3,500 units divided among the parotid and submandibular glands, with repeat treatment generally no more frequent than every 12 weeks. In a Phase III trial of 187 adults, both 2,500-unit and 3,500-unit doses produced significantly greater unstimulated salivary-flow reduction than placebo at week four. Parkinson’s disease accounted for about 65.2% of participants, aligning the product with adult movement-disorder practice.

Adverse events still influence toxin selection and follow-up. In the rimabotulinumtoxinB trial, dry mouth occurred in 38.1% of patients receiving 2,500 units and 45.3% receiving 3,500 units, compared with 8.3% on placebo. Dysphagia occurred in 11.1%, 4.7%, and 1.7%, respectively. Adult neurologic patients often already have swallowing impairment, so clinicians weigh salivary reduction against the risk of worsening dysphagia.

 

Guidelines Keep Treatment Escalation Stepwise

Motor neurone disease guidance from NICE recommends assessment of saliva quantity, viscosity, swallowing, respiratory function, diet, posture, and oral care before treatment selection. Antimuscarinic medicines remain first-line pharmacological treatment, with glycopyrronium preferred where cognitive impairment is a concern because of lower central nervous system penetration. Botulinum toxin A can be considered as first- or second-line treatment, with the relevant recommendation updated in 2024.

Cerebral palsy care pathways usually involve more than prescribing. AACPDM lists anticholinergic medicines, botulinum toxin injections, surgery, and oral-motor or behavioral interventions. Botulinum toxin treatment is temporary and often requires repeat injections at intervals that vary by product and patient response. Pediatric adoption therefore depends on caregiver acceptance, procedural capacity, sedation needs, ultrasound availability, school functioning, and aspiration history.

Adult neurologic guidelines help formalize reimbursement decisions. NICE recommends incobotulinumtoxinA as an option for chronic sialorrhea caused by neurologic conditions in adults. Formal recommendations reduce payer uncertainty and support referral from neurology, rehabilitation, ENT, and dental specialists when oral medicines fail or cannot be tolerated.

 

Reimbursement Milestones Are Expanding Injection Access

Australia created one of the clearest recent access pathways for incobotulinumtoxinA. The Pharmaceutical Benefits Advisory Committee recommended Xeomin for chronic sialorrhea in May 2025, and PBS listing began on March 1, 2026. The Medical Services Advisory Committee also supported a corresponding injection service, covering patients aged two years and older with chronic sialorrhea caused by neurologic or neurodevelopmental disorders, with treatment no more frequently than every 16 weeks.

Subsidy changes can materially affect uptake because toxin treatment involves both drug cost and administration cost. The Australian Government stated that eligible patients would pay a maximum of AUD 25 per script, or AUD 7.70 with a concession card, compared with more than AUD 1,400 without subsidy. Funding the medicine without funding the injection pathway would leave a major access barrier; Australia addressed both parts of the treatment chain.

Japan also moved from specialist need to approved-product availability. Teijin Pharma and Merz announced Japanese approval of XEOMIN for chronic sialorrhea in June 2025, describing it as the first approved drug for the indication in Japan. That approval gives Merz an early position in a market where physician training, gland-injection technique, and referral awareness will shape adoption.

 

Procedural and Non-Drug Options Remain Refractory-Patient Tools

Surgery, radiotherapy, salivary-gland ablation, cryoablation, and neuromodulation serve patients who do not respond to medicines or cannot tolerate repeated pharmacological treatment. These approaches are unlikely to displace oral anticholinergics or botulinum toxin broadly, but they can compete for severe refractory patients who cycle through medicines, suctioning, and repeated injections.

ALS illustrates the evidence gap. Small studies of botulinum toxin B and salivary-gland radiotherapy suggest symptom improvement in selected patients, but a Cochrane review found limited evidence with small samples and uncertainty around treatment effects. Refractory ALS care will continue to rely on individualized decisions that balance secretion control, swallowing safety, respiratory function, and comfort.

Hospital-based use is beginning to appear in acute neurologic care. A 2025 case series of six critically ill patients with acute neurological injuries and refractory sialorrhea reported reduced documented drooling and suctioning requirements after salivary-gland botulinum toxin A injections, with no injection-related adverse events. The evidence is too small for broad adoption assumptions, but it signals interest from neurocritical-care teams managing suctioning burden and aspiration risk.

Electrical and sensory stimulation trials remain early. Recent ClinicalTrials.gov records include neuromuscular electrical stimulation added to oral-motor therapy for children with cerebral palsy, transcutaneous electrical nerve stimulation, auricular vagus-nerve stimulation in Parkinson’s disease, and local vibration therapy. These approaches could become adjunctive rehabilitation tools if they reduce drooling without anticholinergic effects or gland-injection burden.

 

Supplier Positioning Depends on Label Breadth, Repeat Use, and Access Support

Merz has the strongest branded toxin position because XEOMIN covers adult and pediatric chronic sialorrhea, has U.S. approval down to age two, and continues to add regional access milestones. Australia’s PBS/MBS pathway and Japan’s first approved-product status strengthen the brand’s role beyond clinical efficacy. Repeat-treatment scheduling, ultrasound-guided injection support, physician training, and pediatric usability are central to the franchise.

US WorldMeds’ MYOBLOC holds a narrower but durable adult position as a botulinum toxin B product. Adult neurologic use, a 12-week retreatment schedule, and an alternate toxin profile support its role when clinicians prefer botulinum toxin B or when prior toxin response and tolerability influence selection.

Oral glycopyrrolate and glycopyrronium suppliers retain a practical advantage in first-line pediatric care. Families and clinicians often prefer a medicine that can be started without procedural referral. The trade-off is systemic anticholinergic burden, which keeps some patients moving toward botulinum toxin or procedural care.

Off-label and generic anticholinergic options continue to constrain pricing in many settings. Scopolamine patches, atropine drops, benztropine, trihexyphenidyl, amitriptyline, and related therapies remain part of practice where labeled options are unavailable, unaffordable, or poorly reimbursed. Branded products need clearer advantages in duration, tolerability, pediatric dosing, caregiver outcomes, and payer coverage to hold premium positioning.

 

Regional Market Behavior

North America has the strongest adult and pediatric treatment infrastructure. The United States has labeled options across pediatric oral glycopyrrolate, adult and pediatric incobotulinumtoxinA, and adult rimabotulinumtoxinB. Parkinson’s disease, cerebral palsy, ALS, stroke, traumatic brain injury, and clozapine-treated schizophrenia provide multiple referral pools, but treatment uptake depends on specialist recognition and coverage for repeat procedures.

Europe combines pediatric glycopyrronium access with established botulinum toxin guidance. Sialanar supports severe pediatric drooling in neurologic disorders, while incobotulinumtoxinA has a defined role in chronic sialorrhea caused by neurologic conditions. European adoption is likely to favor therapies with caregiver-reported benefit, guideline support, and predictable repeat-treatment requirements.

Asia-Pacific is moving from limited formal options toward approved and reimbursed pathways. Japan’s approval of XEOMIN created a first approved drug route for chronic sialorrhea. Australia’s PBS and injection-service support created a more complete access model by reducing both medicine and administration barriers. Markets that fund both components of toxin treatment are better positioned to expand use beyond a small number of specialist centers.

 

Market Outlook

Sialorrhea treatment will grow through better conversion of neurologic disease burden into treated chronic drooling populations. Parkinson’s disease and cerebral palsy provide the largest recurring pools. ALS, stroke, traumatic brain injury, and clozapine-induced sialorrhea provide smaller but high-need segments where treatment can affect aspiration risk, care intensity, medication adherence, and quality of life.

Oral anticholinergics will continue to dominate early pharmacological treatment because they are accessible and non-procedural. Anticholinergic adverse effects will keep growth from becoming purely volume-led. Botulinum toxin products will gain share where patients need localized secretion control, repeatable benefit, and reduced systemic drug exposure.

XEOMIN is best positioned among branded toxin products because it combines adult and pediatric labeling, repeat-treatment economics, and expanding regional access. MYOBLOC remains relevant in adult chronic sialorrhea through botulinum toxin B differentiation. Glycopyrronium products remain important in pediatric care but must compete with tolerability limits and procedural alternatives.

Reimbursement will decide how quickly diagnosed need becomes treated demand. Australia’s PBS and MBS model shows how funding the drug and the injection service together can remove two major access barriers. Japan’s first approved-product milestone gives Merz a market-creation role. U.S. growth will depend on payer authorization, specialist capacity, and stronger identification of sialorrhea in Parkinson’s disease, cerebral palsy, ALS, post-stroke care, and psychiatric treatment.

Suppliers with pediatric usability, repeat-treatment predictability, training support, regional reimbursement access, and evidence beyond salivary-flow reduction will hold the strongest position in the Sialorrhea Treatment Market.

 

Sialorrhea Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 734 Million
Revenue Forecast in 2032	USD 1.08 Billion
Overall Growth Rate	CAGR of 5.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Disease Indication, By Patient Group, By End User, By Geography
By Treatment Type	Oral Anticholinergic Medicines, Botulinum Toxin Injections, Surgical and Interventional Procedures, Radiotherapy
By Disease Indication	Parkinson’s Disease, Cerebral Palsy, Amyotrophic Lateral Sclerosis, Stroke and Traumatic Brain Injury, Clozapine-Induced Sialorrhea, Neurodevelopmental Disorders
By Patient Group	Pediatric Patients, Adult Patients
By End User	Hospitals, Neurology Clinics, Pediatric Specialty Clinics, Rehabilitation Centers, ENT Clinics, Long-Term Care and Home-Care Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Japan, China, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising neurological disease burden Increasing prevalence of Parkinson’s disease and cerebral palsy Expanding access to botulinum toxin therapies
Customization Option	Available upon request